Abstract: A crystalline Form II of 17?-N-[2,5-bis (trifluoromethyl)phenyl]carbamoyl-4-aza-5-?-androst-1-en-3-one (dutasteride) is provided. The preferred crystalline Form II of dutasteride has an X-ray powder diffraction pattern, expressed in terms of d-spacing (in ° A), with peaks at about 13.42, 6.96, 6.13, 5.27, 4.77, 4.70, 4.58, 4.46 and 3.82. A process for preparation of a crystalline Form II of dutasteride is also provided and includes dissolving a crude form of dutasteride in an alcoholic solvent having from 1 to 5 carbon atoms; removing the alcoholic solvent to obtain a residue; adding an ester solvent to the residue; and filtering the resulting separated solids. The processes of the invention are believed to be simple, eco-friendly, and commercially viable.

Abstract: An improved process for making crystalline Form-I of Pantoprazole sodium sesquihydrate is provided.

Abstract: A novel amorphous form of cetirizine and processes for making the amorphous form as well as compositions, pharmaceutical compositions, and methods utilizing the crystalline form are described.

Abstract: The present invention relates to an improved and convenient process for the preparation of 3-Ethoxy-4-(alkoxy carbonyl)-phenyl acetic acid, which can be represented by formula (Ia) where R1 represents ethyl or methyl.

Abstract: The present invention relates to crystalline form II of esomeprazole trihydrate and methods of its preparation and use. Preferably, the crystalline form II of esomeprazole trihydrate has an X-ray powder diffraction pattern that includes five or more peaks with 2 theta angles of 4.82±0.09, 5.55±0.09, 7.41±0.09, 8.60±09, 12.10±0.09, 14.16±0.09, 18.47±0.09, and 21.08±0.09.

Abstract: An amorphous rosiglitazone maleate and its preparation as well as uses thereof for a pharmaceutical composition and a method for medical treatment including combination therapy are described.

Abstract: The invention relates to novel crystalline form VI of Donepezil hydrochloride and process for preparing the crystalline form VI, which is a simple, non-hazardous and commercially viable process.

Abstract: The present invention is directed to a crystalline Form C of omeprazole sodium and the related process of its preparation, a crystalline Form D of omeprazole sodium and the related process of its preparation, and a process for preparation of crystalline Form A of omeprazole sodium.

Abstract: An improved process for making crystalline Form-I of Pantoprazole sodium sesquihydrate is provided.

Abstract: The present invention relates to crystalline and amorphous forms of dextrorotatory dihydrochloride salt of cetirizine, the process for the preparation thereof and compositions containing the same. The invention also relates to the crystalline and amorphous forms of levorotatory dihydrochloride salt of cetirizine, the process for the preparation thereof and compositions containing the same. Both crystalline and amorphous salt forms of cetirizine dihydrochloride are suitable for pharmaceutical purposes in the treatment of allergies, including ailments such as chronic and acute allergic rhinitis, allergic conjunctivitis, pruritus, urticaria and the like.

Abstract: The present invention relates to novel crystalline Form Z of rabeprazole sodium and a process for the preparation of the crystalline Form Z as well as composition, pharmaceutical composition and method utilizing the crystalline Form Z.

Abstract: A hydrate of esomeprazole magnesium in the form of an amorphous solid is provided. Methods of preparation and use of, as well as formulation containing the hydrate of esomeprazole magnesium in the form of an amorphous solid are also provided.

Abstract: The present invention is related to crystalline forms of ziprasidone and its hydrochloride salt and an amorphous form of ziprasidone hydrochloride and the process for the preparation thereof. The crystalline forms and amorphous form of the invention are suitable for pharmaceutical purposes in the treatment of psychosis. The processes of the invention are simple, non-hazardous and commercially suitable.

Abstract: The present invention is directed to novel anhydrous crystalline form of Levofloxacin is depicted as Formula (I), further more its process for preparation thereof. The process for the preparation of novel anhydrous crystalline form of Levofloxacin comprises the condensation of N-Methyl piperazine with S(−)-9,10-difluoro-7-oxo 2,3-dihydro 7H-pyrido[1,2,3-DE] [1,4] Benzoxazine-6-carboxylic acid in Acetonitrile followed by distillation of solvent to afford the residue, the resultant residue is refluxed with toluene and the solid is filtered at room temperature to afford the Levofloxacin. Thus resulted Levofloxacin is further refluxed in Acetonitrile and filtered the Novel anhydrous crystalline form of Levofloxacin as undissolved material. The anhydrous crystalline form of Levofloxacin is characterized by X-ray diffractogram, Differential Scanning Calorimetry thermogram and Infrared Spectra.

Abstract: The present invention relates to an amorphous form of Sumatriptan succinate of Formula (1). The present invention also relates to process for the preparation of an amorphous form of Sumatriptan succinate. The process for the preparation of an amorphous form of Sumatriptan succinate comprises refluxing an aqueous mixture of Sumatriptan or its succinate salt in alcoholic solvents such as methanol or nitrile solvents such as acetonitrile followed by evaporation of the solvent from the filtrate. The resulting residue is triturated with water immiscible aromatic or aliphatic hydrocarbon solvents such as cyclohexane to afford an amorphous form of Sumatriptan succinate.

Abstract: An efficient process for preparation of donepezil is provided.

Abstract: The present invention relates to the amorphous form of levocetirizine dihydrochloride. The present invention also relates to the process for the preparation of the amorphous form of levocetirizine dihydrochloride. The amorphous form of levocetirizine dihydrochloride is suitable for pharmaceutical purposes in the treatment of allergies, including ailments such as chronic and acute allergic rhinitis, allergic conjunctivitis, pruritus, urticaria and the like.

Abstract: The present invention relates to crystalline and amorphous forms of repaglinide and the process for the preparation thereof. In particular, a new crystalline Form III of S-repaglinide is described and the process for its preparation is provided. Both the crystalline and amorphous forms of repaglinide are suitable for pharmaceutical purposes in the treatment of diabetes. The processes of the invention are simple, non-hazardous and commercially suitable.

Abstract: A compound that is a crystalline Form III of losartan potassium is provided. Also provided are compositions containing the compound and methods for its preparation.

Abstract: A process of preparation of optically pure or optically enriched isomers of omeprazole and structurally related sulfoxides is provided. Also provided are an amorphous form of esomeprazole, as well a pharmaceutical composition containing it and a method of using it for treatment of gastric disorders.